#United States #New York #Class Action #Investor Rights #Neumora Therapeutics

Class Action Lawsuit Against Neumora Therapeutics, Inc.

A formal class action lawsuit has been initiated against Neumora Therapeutics, Inc., a company noted for its developments in the pharmaceutical sector, particularly in treating mental health conditions. This legal action, spearheaded by The Gross Law Firm, is aimed at securing recovery for investors who have faced losses due to alleged deceptive practices and misleading statements made by the company.

Background

The Gross Law Firm has recently issued an announcement concerning shareholders of Neumora Therapeutics, identified by the NASDAQ ticker NMRA. Shareholders who acquired NMRA shares during the specified class period are encouraged to reach out to the firm for potential roles as lead plaintiffs. It's important to note that being appointed as a lead plaintiff is not a prerequisite for investors wishing to participate in the lawsuit.

The lawsuit covers individuals or entities that purchased Neumora common stock from approximately September 15, 2023, and extends to all those who may have been impacted by questionable company practices. Investors are urged to act promptly, as the deadline to register for participation in this class action is April 7, 2025.

Allegations Against Neumora

The core of the lawsuit revolves around significant allegations against Neumora Therapeutics. The complaint asserts that during the class period, Neumora issued materially misleading or false statements. Crucially, it is alleged that the company made adjustments to the Phase Two trial inclusion criteria for its flagship drug Navacaprant. This adjustment was necessary to support the justification for initiating its Phase Three Program, particularly regarding the treatment of moderate to severe Major Depressive Disorder (MDD).

Additionally, the lawsuit claims that investigators selectively altered the statistical analysis plans within the Phase Two trials, specifically targeting patients diagnosed with moderate to severe MDD. Such modifications were purportedly made without adequate data, suggesting that the trials lacked sufficient participant numbers and a representative balance of male and female subjects. These inadequacies call into question the reliability of the predictions relating to the results of the KOASTAL-1 study.

Next Steps for Shareholders

Shareholders who wish to register for the class action can do so without incurring costs or obligations. Once registered, investors will be included in a monitoring software service, which will provide updates throughout the legal proceedings. With the lead plaintiff deadline approaching, shareholders are urged to secure their positions without delay.

Why Choose The Gross Law Firm?

The Gross Law Firm operates nationally and specializes in class action lawsuits, particularly dealing with investor rights and business malpractice. Their mission revolves around protecting the interests of investors who have suffered losses due to fraudulent or unlawful activities conducted by companies. With a commitment to holding corporations accountable, the firm aims for recovery on behalf of those misled by companies, ensuring their stakeholders engage in responsible practices.

For those impacted by the alleged misconduct at Neumora Therapeutics, this lawsuit represents a crucial opportunity to reclaim potential losses. Interested shareholders can contact The Gross Law Firm directly at their New York office or via the provided email and phone number for further inquiries. It's critical for affected individuals to take proactive steps and become part of the effort to seek justice and accountability in the pharmaceutical sector.

Contact Information

For more guidance, individuals can reach out to:

• - The Gross Law Firm

15 West 38th Street, 12th Floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

Stay informed and participate as necessary to protect your investments.